S-0.1, r. 12

Regulation respecting drugs that a midwife may prescribe or administer in the practice of midwifery

Replaced on 03March 011 2021

chapter S-0.1, r. 12

Regulation respecting drugs that a midwife may prescribe or administer in the practice of midwifery

MIDWIVES — DRUGS

Midwives Act

(chapter S-0.1, s. 9, 1st par.).

S-0.1

09September 011 2012

1. The drugs that a midwife may prescribe or administer are

(1)  the drugs for the mother listed in Schedule I, on the conditions, if applicable, determined in the Schedule; and

(2)  the drugs for the child listed in Schedule II, on the conditions determined in the Schedule.

O.C. 967-2008, s. 1.

2. (Omitted).

O.C. 967-2008, s. 2.

SCHEDULE I

(s. 1)

DRUGS THAT A MIDWIFE MAY PRESCRIBE OR ADMINISTER TO THE MOTHER

Substances Specifications and conditions

Acetaminophen For use during the prenatal and postpartum
period

Acetaminophen and codeine Pharmaceutical form containing 325 mg or less
(in combination) of acetaminophen and 30 mg or less of codeine
per tablet
Limited quantity for a 2-day period

Acetaminophen, caffeine and Pharmaceutical form containing 300 mg or less
codeine (in combination) of acetaminophen, 15 mg or less of caffeine
and 8 mg or less of codeine per tablet
Limited quantity for a 2-day period

Alginic acid

Aluminum hydroxide and magnesium hydroxide

Ampicillin Pharmaceutical form for parenteral
administration in prophylaxis during the
prolonged rupture of membranes in asymptomatic
women or in prophylaxis in respect of
beta-hemolytic streptococcus

Betamethasone, clotrimazole and Pharmaceutical form for topical administration
mupirocin (in combination) in a concentration of 0.1% betamethasone, 10%
clotrimazole and 2% mupirocin for the
treatment of fungal infections on nipples of
breastfeeding women

Betamethasone, miconazole and Pharmaceutical form for topical administration
mupirocin (in combination) in a concentration of 0.1% betamethasone, 2%
miconazole and 2% mupirocin for the treatment
of fungal infections on nipples of
breastfeeding women

Calcium carbonate

Calcium gluconate Pharmaceutical form for parenteral
administration in a concentration of 10% as
antidote for magnesium sulphate while awaiting
transfer of clinical responsibility to a
physician

Carboprost tromethamine Pharmaceutical form for parenteral
administration in a concentration of 0.25 mg
in prophylaxis or if hemorrhage during the
immediate postpartum period and synthetic
oxytocin is ineffective

Clindamycin Pharmaceutical form for parenteral
administration in prophylaxis in respect of
beta-hemolytic streptococcus, if allergy to
penicillin G

Clotrimazole Pharmaceutical forms for topical and vaginal
administration in a concentration of 1%

Dextrose Pharmaceutical form for parenteral infusion
administration in a concentration of 5%
Or
Pharmaceutical form for oral administration
for a glucose tolerance test

Dextrose and sodium chloride Pharmaceutical form for parenteral infusion
(in combination) administration in a concentration of 5%
dextrose and 0.45% sodium chloride

Diazepam Pharmaceutical form for rectal administration
for the treatment of seizures, if magnesium
sulphate is ineffective

Diphenhydramine hydrochloride Pharmaceutical form for parenteral
administration for the treatment of allergic
reactions, with or without anaphylactic
reaction, with no increased body temperature
or systemic illness

Docusate calcium Pharmaceutical form for oral administration
during the prenatal and postpartum period

Docusate sodium Pharmaceutical form for oral administration
during the prenatal and postpartum period

Doxylamine succinate and Pharmaceutical form containing 10 mg of
pyridoxine hydrochloride doxylamine succinate and 10 mg of pyridoxine
(in combination) hydrochloride per tablet

Epinephrine Presented in the form of auto-injector or
ampoule in a concentration of 1 mg/ml for the
emergency treatment of anaphylactic reactions

Ergonovine maleate Pharmaceutical form for parenteral
administration in prophylaxis or if hemorrhage
during the immediate postpartum period and
synthetic oxytocin is ineffective

Erythromycin Pharmaceutical form for parenteral
administration in prophylaxis in respect of
beta-hemolytic streptococcus, if allergy to
penicillin G and resistance to clindamycin

Ferrous fumarate Pharmaceutical form for oral administration,
if intolerance to ferrous sulphate

Ferrous gluconate Pharmaceutical form for oral administration,
if intolerance to ferrous sulphate or ferrous
fumarate

Ferrous sulphate Pharmaceutical form for oral administration

Folic acid Pharmaceutical form for oral administration
during the prenatal period

Glycerin Pharmaceutical form for rectal administration

Hamamelis and glycerin Pharmaceutical form for topical administration
(in combination) in a concentration of 50% hamamelis

Human immunoglobulin Pharmaceutical form for parenteral
administration during the prenatal and
postpartum period

Hydrocortisone and zinc Pharmaceutical form for rectal administration
sulphate (in combination) in a concentration of 0.5% hydrocortisone and
0.5% zinc sulphate

Ibuprofen For use during the postpartum period

Lidocaine Pharmaceutical form for topical administration
in a concentration of 4% for action on vaginal
mucus while repairing minor lacerations
Or
Pharmaceutical form for parenteral
administration in a concentration of 1%

Lorazepam Pharmaceutical forms for oral and sublingual
administration for manual removal of the
placenta, if hemorrhage

Magnesium sulphate Pharmaceutical form for parenteral
administration for the treatment of seizures

Miconazole Pharmaceutical forms for topical and vaginal
administration during the prenatal period in a
concentration of 2%

Misoprostol Pharmaceutical forms for oral or rectal
administration if hemorrhage during the
immediate postpartum period or synthetic
oxytocin is ineffective or unavailable

MMR vaccine Pharmaceutical form for parenteral
administration during the postpartum period

Morphine Pharmaceutical form for parenteral
administration during the neonatal period in
prolonged latency in primiparous women and
during the postpartum period

Multivitamins and minerals

Nitroglycerin Pharmaceutical form for sublingual spray
administration if excessive uterine activity
with a non-reassuring fetal heart rate or
prolapsed cord

Penicillin G Pharmaceutical form for parenteral
administration in prophylaxis in respect of
beta-hemolytic streptococcus

Psyllium (mucilage) Pharmaceutical form for oral administration
during the prenatal and postpartum period

Ringer’s lactate Pharmaceutical form for parenteral infusion
administration for fluid replacement if
substantial postpartum loss of blood or if
hemorrhage

Sodium chloride Pharmaceutical form for parenteral infusion
administration in a concentration of 0.9% for
fluid replacement if substantial postpartum
loss of blood, if hemorrhage or for dilution

Sodium citrate/sodium lauryl Pharmaceutical form for rectal administration
sulfate

Synthetic oxytocin Pharmaceutical form for parenteral
administration in prophylaxis or if hemorrhage
during the immediate postpartum period

Terconazole Pharmaceutical forms for topical and vaginal
administration during the prenatal period in a
concentration of 0.4%, if clotrimazole and
miconazole are ineffective

Vitamin B6 Pharmaceutical form for oral administration
for the treatment of nausea during the
prenatal period

Vitamin B12 For use during the prenatal period

Vitamin D and calcium Pharmaceutical form for oral administration in
(in combination) prophylaxis

O.C. 967-2008, Sch. I.

SCHEDULE II

(s. 1)

DRUGS THAT A MIDWIFE MAY PRESCRIBE OR ADMINISTER TO THE CHILD

Substances Specifications and conditions

Ampicillin Pharmaceutical form for parenteral
administration in newborns having an emergency
condition and after a medical consultation

Epinephrine Pharmaceutical forms for parenteral and
endotracheal administration in a concentration
of 0.1 mg/ml during neonatal resuscitation

Erythromycin Pharmaceutical form for ophthalmic
administration in a concentration of 0.5% in
prophylaxis in newborns

Gentamicin Pharmaceutical form for parenteral
administration in newborns having an emergency
condition and after a medical consultation

Gentian violet Pharmaceutical form for topical
administration, in a water solution, in a
concentration of 1% or less

Hepatitis B immune globulin Pharmaceutical form for parenteral
administration

Hepatitis B vaccine Pharmaceutical form for parenteral
administration

Naloxone hydrochloride Pharmaceutical form for parenteral
administration in a concentration of 0.4 mg/ml
in newborns having an emergency condition

Nystatin Pharmaceutical form for oral administration,
presented in the form of a suspension for the
treatment of non-recurrent, non- resistant
oral mycosis

Penicillin G Pharmaceutical form for parenteral
administration in newborns having an emergency
condition and after a medical consultation

Sodium chloride Pharmaceutical form for parenteral infusion
administration in a concentration of 0.9% in
newborns having an emergency condition or for
dilution

Vitamin D Pharmaceutical form for oral administration in
breastfed infants

Vitamin K1 Pharmaceutical form for parenteral and
oral administration

O.C. 967-2008, Sch. II.

REFERENCES

O.C. 967-2008, 2008 G.O. 2, 5005